IRVINE, Calif.--(BUSINESS WIRE)--Endologix, Inc. (NASDAQ: ELGX), a developer and marketer of innovative treatments for aortic disorders, today honored four innovators of aortic therapy at the 45 th ...

New York, NY – VEITHsymposium and the Cardiovascular Research Foundation (CRF) are pleased to announce an alliance between Transcatheter Cardiovascular Therapeutics (TCT) and the VEITHsymposium. TCT ...

Now in its 45th year, VEITHsymposium provides vascular surgeons, interventional radiologists, interventional cardiologists and other vascular specialists with a unique and exciting format to learn the ...

DURHAM, N.C., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at ...

aXess demonstrated exceptional patency rates and no infections to date EINDHOVEN, The Netherlands – 17 November 2023, Xeltis, a leading developer of transformative implants that enable the natural ...

MOUNTAIN VIEW, CA--(Marketwired - Nov 16, 2015) - Hansen Medical, Inc. (NASDAQ: HNSN), the global leader in intravascular robotics, today announced it will exhibit its Magellan™ Robotic System at the ...

Primary patency maintained at 12 months in 80% of per protocol analysis population The primary safety endpoint is defined as the number of subjects with a composite of freedom from Major Adverse Limb ...

Outstanding 12-month first-in-human data from Xeltis’ aXess hemodialysis vascular conduit trial presented at VEITHsymposium 2023 aXess demonstrated exceptional patency rates and no infections to date ...